Recent News

• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference
• 05.29.2025 - Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
• 05.29.2025 - Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
• 05.13.2025 - Bank of America 2025 Health Care Conference
• 05.13.2025 - Bank of America 2025 Health Care Conference
• 05.12.2025 - Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
• 05.12.2025 - Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
• 05.12.2025 - Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
• 05.12.2025 - Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

Recent Filings

• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2025 - EX-99.1 EX-99.1
• 05.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.12.2025 - 8-K Current report
• 05.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.29.2025 - ARS Annual Report to Security Holders
• 04.29.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.29.2025 - DEF 14A Other definitive proxy statements